BFRI Biofrontera Inc.
Company Updates ·
The company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027.
Net product revenue rose 32.9% from a year earlier, and gross margin reached 80%. The net loss was $0.6 million, compared with $5.3 million in the prior-year quarter.
Revenue rose about 17% to $10.1 million in the first quarter. Nasdaq confirmed on May 6, 2026 that the company had regained compliance with its minimum bid price requirement.
Only $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024.
Biofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement.
The company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake.
Biofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $41.7 million | $37.3 million |
| Research and development | $3.7 million | $2.1 million |
| Net income (loss) | -$10.5 million | -$17.8 million |
| Cash from operations | -$13.4 million | -$10.3 million |
| Cash and equivalents | $6.4 million | $5.9 million |
Biofrontera Inc. trades under the ticker BFRI on NASDAQ.
Biofrontera Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Biofrontera Inc. is 1858685. Its filings are on SEC EDGAR.
14,852,359 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Biofrontera Inc. under United States.
Our directory classifies Biofrontera Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Biofrontera Inc. is US09077D2099.
aibio.space lists Biofrontera Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$41.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Biofrontera Inc. reported a net loss of $10.5 million for the fiscal year ended Dec 31, 2025, and used $13.4 million of cash in operations, per its annual report to the SEC.
$3.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$4.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Biofrontera, dated Sep 14, 2026: "Biofrontera gets FDA approval for Ameluz in superficial basal cell carcinoma". The company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027. Source.
Our latest financing story, dated Jun 30, 2025: "Biofrontera agrees $11.0 million preferred stock sale to fund U.S. Ameluz rights deal". The company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio